U.S. patent application number 10/731258 was filed with the patent office on 2005-01-13 for contact lens packages containing additives.
Invention is credited to Arnold, Steven C., Dubey, Dharmesh, Li, Yufu, Peck, James M., Tokarski, Michael G., Zhang, Qiang.
Application Number | 20050006255 10/731258 |
Document ID | / |
Family ID | 32713054 |
Filed Date | 2005-01-13 |
United States Patent
Application |
20050006255 |
Kind Code |
A1 |
Peck, James M. ; et
al. |
January 13, 2005 |
Contact lens packages containing additives
Abstract
A package having an additive that does not adhere to a medical
device enclosed therein.
Inventors: |
Peck, James M.;
(Jacksonville, FL) ; Dubey, Dharmesh;
(Jacksonville, FL) ; Tokarski, Michael G.; (Ponte
Vedra Beach, FL) ; Zhang, Qiang; (Annandale, NJ)
; Li, Yufu; (Bridgewater, NJ) ; Arnold, Steven
C.; (Sparta, NJ) |
Correspondence
Address: |
PHILIP S. JOHNSON
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK
NJ
08933-7003
US
|
Family ID: |
32713054 |
Appl. No.: |
10/731258 |
Filed: |
December 9, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60436109 |
Dec 23, 2002 |
|
|
|
Current U.S.
Class: |
206/5.1 |
Current CPC
Class: |
A45C 11/005 20130101;
A45C 11/046 20130101; B65B 55/22 20130101; B65B 25/008 20130101;
A61L 12/086 20130101; A61J 1/00 20130101 |
Class at
Publication: |
206/005.1 |
International
Class: |
A45C 011/04 |
Claims
What is claimed is:
1. A package for storing medical devices in a solution comprising a
molded base wherein the molded base comprises an additive, provided
that the medical device is not a contact lens consisting of
acqualfilcon A coated with polyHema.
2. The package of claim 1 wherein the additive is selected from the
group consisting of succinic acid, glycerol monostearate, PVP, and
PVP/maleic anhydride.
3. The package of claim 1 wherein the additive is glycerol
monostearate.
4. The package of claim 3 wherein glycerol monostearate is present
at a concentration of greater than about 0.5 weight percent to
about 5 weight percent.
5. The package of claim 3 wherein glycerol monostearate is present
at a concentration of about 2 percent.
6. The package of claim 1 wherein the additive is PVP KD90.
7. The package of claim 6 wherein the PVP concentration is about 1%
to about 5%.
8. The package of claim 6 wherein the PVP concentration is about
1.0%.
9. The package of claim 1 wherein the additive is PVP KD90/maleic
anhydride.
10. The package of claim 9 wherein the PVP KD90/maleic anhydride
concentration is about 1/1% to about 5/5%.
11. The package of claim 1 wherein the medical device is a contact
lens which comprises balafilcon A, lotrafilcon A, galyfilcon,
senofilcon, or lenses disclosed in U.S. patent application Ser. No.
60/318,536, entitled Biomedical Devices Containing Internal wetting
Agents," filed on Sep. 10, 2001 and its non-provisional counterpart
of the same title, filed on Sep. 6, 2002.
12. The package of claim 11 wherein the contact lens comprises
Simma 2 and mPDMS.
13. The package of claim 11 wherein the contact lens comprises
Simma 2
14. The package of claim 1 wherein the molded base comprises
polypropylene.
15. The package of claim 1 further comprising a cavity formed in
said molded base wherein said cavity comprises an inner surface,
wherein said inner surface has an average roughness of about 0.5
.mu.m to about 20 .mu.m.
16. The package of claim 15 wherein the inner surface has an
average roughness of about 1.8 .mu.m to about 4.5 .mu.m.
17. The package of claim 15 wherein the inner surface has an
average roughness of about 1.9 .mu.m to about 2.1 .mu.m
18. The package of claim 15 wherein the inner surface has an
average roughness of about 0.5 .mu.m to about 0.8 .mu.m.
19. The package of claim 1 further comprising a cavity formed in
said molded base wherein said cavity comprises an inner surface,
wherein said inner surface has an average roughness of about 0.5
.mu.m to about 20 .mu.m and the additive is glycerol monostearate
or PVP.
20. The package of claim 19 wherein the average roughness of the
inner surface is about 0.5 .mu.m to about 0.8 .mu.m and the
concentration of PVP is about 1%.
21. The package of claim 19 wherein the inner surface has an
average roughness of about 1.9 .mu.m to about 2.1 .mu.m and the
concentration of PVP is about 1%.
22. The package of claim 1 further comprising a cavity formed in
said molded base wherein said cavity comprises an inner surface,
wherein said inner surface has an average roughness of about 0.5
.mu.m to about 20 .mu.m and the additive is maleic anhydride or
PVP/maleic anhydride.
23. The package of claim 22 wherein the average roughness of the
inner surface is about 0.5 .mu.m to about 0.8 .mu.m and the
concentration of PVP/maleic anhydride is about 1%.
24. The package of claim 22 wherein the inner surface has an
average roughness of about 1.9 .mu.m to about 2.1 .mu.m and the
concentration of PVP/maleic anhydride is about 1%.
25. The package of claim 22 wherein the average roughness of the
inner surface is about 0.5 .mu.m to about 0.8 .mu.m and the
concentration of maleic anhydride is about 1%.
26. The package of claim 22 wherein the inner surface has an
average roughness of about 1.9 .mu.m to about 2.1 .mu.m and the
concentration of maleic anhydride is about 1%.
27. A method of reducing the adherence of a medical device to its
packaging, comprising storing said medical device in a solution in
a package comprising a molded base wherein said molded base
comprises an additive, provided that the medical device is not a
contact lens consisting of acqualfilcon A coated with polyHema.
28. The method of claim 27 wherein additive is selected from the
group consisting of succinic acid, glycerol monostearate, and
PVP.
29. The method of claim 27 wherein the additive is glycerol
monostearate.
30. The method of claim 27 wherein glycerol monostearate is present
at a concentration of greater than about 0.25 weight percent to
about 5 weight percent.
31. The method of claim 27 wherein glycerol monostearate is present
at a concentration of about 2 percent.
32. The method of claim 27 wherein the additive is PVP KD90.
33. The method of claim 27 wherein the PVP is present at about 1%
to about 5%.
34. The method of claim 27 wherein the contact lens comprises
balafilcon A, lotrafilcon A, or lenses disclosed in U.S. patent
application Ser. No. 60/318,536, entitled Biomedical Devices
Containing Internal wetting Agents," filed on Sep. 10, 2001 and its
non-provisional counterpart of the same title, filed on Sep. 6,
2002.
35. The method of claim 27 wherein the contact lens comprises Simma
2
36. The method of claim 27 wherein the molded base comprises
polypropylene.
37. The method of claim 27 further comprising a cavity formed in
said molded base wherein said cavity comprises an inner surface,
wherein said inner surface has an average roughness of about 0.5
.mu.m to about 20 .mu.m and the additive is glycerol monostearate
or PVP.
38. The method of claim 37 wherein the average roughness of the
inner surface is about 0.5 .mu.m to about 0.8 .mu.m and the
concentration of PVP is about 1%.
39. The method of claim 37 wherein the inner surface has an average
roughness of about 1.9 .mu.m to about 2.1 .mu.m and the
concentration of PVP is about 1%.
40. The method of claim 27 further comprising a cavity formed in
said molded base wherein said cavity comprises an inner surface,
wherein said inner surface has an average roughness of about 0.5
.mu.m to about 20 .mu.m and the additive is maleic anhydride or
PVP/maleic anhydride.
41. The method of claim 40 wherein the average roughness of the
inner surface is about 0.5 .mu.m to about 0.8 .mu.m and the
concentration of PVP/maleic anhydride is about 1%.
42. The method of claim 40 wherein the inner surface has an average
roughness of about 1.9 .mu.m to about 2.1 .mu.m and the
concentration of PVP/maleic anhydride is about 1%.
43. The method of claim 40 wherein the average roughness of the
inner surface is about 0.5 .mu.m to about 0.8 .mu.m and the
concentration of maleic anhydride is about 1%.
44. The method of claim 40 wherein the inner surface has an average
roughness of about 1.9 .mu.m to about 2.1 .mu.m and the
concentration of maleic anhydride is about 1%.
45. A method of hydrating a contact lens comprising, consisting
essentially of, or consisting of hydrating said lens in a molded
base wherein said molded base comprises an additive.
46. The method of claim 45 wherein the additive is selected from
the group consisting of succinic acid, glycerol monostearate, PVP,
and PVP/maleic anhydride.
47. The method of claim 46 wherein the additives are present at a
concentration of greater than about 0.25 weight percent to about 5
weight percent.
48. The method of claim 45 wherein the molded base further
comprises a cavity formed in said molded base wherein said cavity
comprises an inner surface, wherein said inner surface has an
average roughness of about 0.5 .mu.m to about 20 .mu.m and the
additive is maleic anhydride or PVP/maleic anhydride.
Description
RELATED APPLICATIONS
[0001] This application is a non-provisional filing of a
provisional application, U.S. patent application Ser. No.
60/436,109, filed on Dec. 23, 2002.
FIELD OF THE INVENTION
[0002] This invention related to packages for storing contact
lenses as well as methods of using and preparing these
packages.
BACKGROUND
[0003] Contact lenses have been used commercially to improve vision
since the 1950s. At first contact lenses were made of hard
materials, which were relatively easy to handle and package for
use, but were uncomfortable for many patients. Later developments,
gave rise to softer more comfortable lenses made of hydrophobic
hydrogels, particularly silicone hydrogels. These lenses are very
pliable, but due to this texture and their chemical composition,
they present a number of problems with packaging.
[0004] Most contact lenses are packaged in individual blister
packages having a bowl portion and a foil top, where the bowl
portion is made from a hydrophobic material such as polypropylene.
See U.S. Pat. Nos. 4,691,820; 5,054,610; 5,337,888; 5,375,698;
5,409,104; 5,467,868; 5,515,964; 5,609,246; 5,695,049; 5,697,495;
5,704,468; 5,711,416; 5,722,536; 5,573,108; 5,823,327; 5,704,468;
5,983,608; 6,029,808; 6,044,966; and 6,401,915 for examples of such
packaging, all of which are hereby incorporated by reference in
their entirety. While polypropylene is resilient enough to
withstand the sterilization steps of contact lens manufacture, this
material has an affinity for contact lenses made of silicone
hydrogels. When silicone hydrogels are packaged in polypropylene
bowls, the lenses stick to the bowl and cannot be removed from the
package without damaging the pliable lenses. Therefore is a need to
prepare a contact lens package that has resilient properties, but
does not stick to the final product. It is this need that is met by
the following invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0005] FIG. 1 illustrates the data for Lens A in different
packages
[0006] FIG. 2 illustrates the data for Lens B in different
packages
[0007] FIG. 3 illustrates the data for Lens C in different
packages
DETAILED DESCRIPTION OF THE INVENTION
[0008] This invention includes a package for storing medical
devices in a solution comprising, consisting essentially of, or
consisting of, a molded base wherein the molded base comprises an
additive, provided that the medical device is not a contact lens
consisting of acqualfilcon A coated with polyHema.
[0009] As used herein a "medical device" is any device that is
stored or packaged in a solution and is used to treat a human
disease. Examples of medical devices include but are not limited to
ophthalmic devices that reside in or on the eye. Ophthalmic devices
includes but are not limited to soft contact lenses, intraocular
lenses, overlay lenses, ocular inserts, and optical inserts. These
devices can provide optical correction or may be cosmetic. The
preferred medical devices of the invention are soft contact lenses
made from silicone elastomers or hydrogels, which include but are
not limited to silicone hydrogels, and fluorohydrogels. Soft
contact lens formulations are disclosed in U.S. patent application
Ser. No. 60/318,536, entitled Biomedical Devices Containing
Internal wetting Agents," filed on Sep. 10, 2001 and its
non-provisional counterpart of the same title, filed on Sep. 6,
2002, U.S. Pat. No. 5,710,302, WO 9421698, EP 406161, JP
2000016905, U.S. Pat. No. 5,998,498, U.S. patent application Ser.
No. 09/532,943, U.S. Pat. No. 6,087,415, U.S. Pat. No. 5,760,100,
U.S. Pat. No. 5,776, 999, U.S. Pat. No. 5,789,461, U.S. Pat. No.
5,849,811, and U.S. Pat. No. 5,965,631. The foregoing references
are hereby incorporated by reference in their entirety. The
particularly preferred medical devices of the invention are soft
contact lenses made from etafilcon A, genfilcon A, lenefilcon A,
polymacon, balafilcon A, lotrafilcon A. and silicone hydrogels as
prepared in U.S. Pat. No. 5,998,498, U.S. patent application Ser.
No. 09/532,943, a continuation-in-part of U.S. patent application
Ser. No. 09/532,943, filed on Aug. 30, 2000, U.S. Pat. No.
6,087,415, U.S. Pat. No. 5,760,100, U.S. Pat. No. 5,776, 999, U.S.
Pat. No. 5,789,461, U.S. Pat. No. 5,849,811, and U.S. Pat. No.
5,965,631. These patents as well as all other patent disclosed in
this application are hereby incorporated by reference in their
entirety. The more particularly preferred medical devices of the
invention are soft contact lenses, balafilcon A, lotrafilcon A,
galyfilcon A, senofilcon A, or those made as described in U.S.
patent application Ser. No. 60/318,536, entitled Biomedical Devices
Containing Internal wetting Agents," filed on Sep. 10, 2001 and its
non-provisional counterpart of the same title, filed on Sep. 6,
2002. The most particularly preferred medical devices are soft
contact lenses made from either galyfilcon A or senofilcon A.
[0010] The term "molded base" refers to any polymer, rubber, or
plastic that can be formed into a receptacle for medical devices,
where the size and shape of the base are determined by the device
and other considerations known those who are skilled in the art of
making or designing molded bases. For example molded bases may be
individual blister packages, secondary packages, or hydrating
trays. The molded base may be prepared from any number of materials
provided that those materials are compatible with the chemical and
physical properties of the device. Examples of suitable materials
include but are not limited to polypropylene, polyethylene, nylons,
olefin co-polymers, acrylics, rubbers, urethanes, polycarbonates,
or fluorocarbons. The preferred materials are metallocenes polymers
and co-polymers made of polypropylene, polyethylene, having a melt
flow range of about 15 g/10 minutes to about 44 g/10 minutes as
determined by ASTM D-1238. With respect to the shape of the molded
base, examples of suitably shaped bases are disclosed in the
following patents which are hereby incorporated by reference in
their entirety, U.S. Pat. Nos. D 458,023; 4,691,820; 5,054,610;
5,337,888; 5,375,698; 5,409,104; 5,467,868; 5,515,964; 5,609,246;
5,695,049; 5,697,495; 5,704,468; 5,711,416; 5,722,536; 5,573,108;
5,823,327; 5,704,468; 5,983,608; 6,029,808; 6,044,966; and
6,401,915. As in the cited references, the molded based is sealed
about the cavity that encloses the contact lens. Flexible cover
sheets can be made from can be an adhesive laminate of an aluminum
foil and a polypropylene film or any other extruded or co-extruded
film that can be sealed to the top surface of the flange in order
to form a hermetic seal for the medical device and the solution.
Further, the base can be formed by any of a number of known methods
which include but are not limited to injection molding, transfer
molding, skin packaging, blow molding, coinjection molding, film
extrusion, or film co-extrusion.
[0011] As used herein the term "additive" refers to a substance
that is added to the polymer, rubber, or plastic prior to forming
the molded base, where the material inhibits sticking, adherence,
or adhesion of the medical device to the molded base. The additive
is mixed with the remainder of the molded base material and amount
of additive present by weight percentage based on the total weight
of the molded base material is greater than about 0.25 to about 10
weight percent, preferably greater than about 0.25 to about 5
weight percent, most preferably about 0.25 to about 3 weight
percent. The preferred additives are glycerol monostearate (2%),
polyvinylpyrolidone (1% to 5%), polyvinylpyrolidone/maleic
anhydride (1/1% to 5/5%), and succinic acid (5%).
Polyvinylpyrolidinone has a variety of molecular weight ranges (as
indicated by the KD#) and consistencies (flake,
powdered/micronized). When PVP KD90 is used as an additive, it is
preferred that it is powered/micronized.
[0012] The term "solution" refers to any liquid medium in which a
medical device is stored. The preferred solutions are aqueous
solutions contain physiological buffers. The particularly preferred
solution is saline solution.
[0013] For example, if the medical device is a contact lens, it is
preferred that the molded base is transparent to the degree
necessary to permit visual inspection, UV sterilization or both.
The preferred additives are glycerol monostearate present at about
2 weight percent, succininc acid present at about 5 weight percent,
PVP KD90 present at about 1-5 weight percent, PVP/maleic anhydride
present at about 1/1 to about 5/5 weight percent. If the inner
surface of the medical device has a roughness of about 0.2 .mu.m to
about 4.5 .mu.m, the preferred additives are maleic anhydride or
PVP/maleic anhydride, most preferably maleic anhydride.
[0014] Further, the invention includes a method of reducing the
adherence of a medical device to its packaging, comprising,
consisting essentially of, or consisting of, storing said medical
device in a solution in a package comprising, consisting
essentially of, or consisting of, a molded base wherein said molded
base comprises an additive, provided that the medical device is not
a contact lens consisting of acqualfilcon A coated with polyHema.
The terms molded base, medical device, solution and additive all
have their aforementioned meanings and preferred ranges.
[0015] When soft contact lenses are prepared, the lenses cured to a
hard disc and subsequently hydrated with water to give the
non-sterilized final product. During this hydration step, soft
contact lenses often stick to the surface of the hydration chamber
and it would useful to find a method of hydrating soft contact
lenses which alleviates this problem.
[0016] To solve this problem, the invention includes a method of
hydrating a contact lens comprising, consisting essentially of, or
consisting of hydrating said lens in a molded base wherein said
molded base comprises an additive. The terms molded base, medical
device, solution and additive all have their aforementioned
meanings. The preferred values for the medical device, the solution
and the additive are as listed above. The preferred molded base is
a square or a rectangle.
[0017] Other have tried to address the problem of a medical device
adhering to its packaging. For example U.S. patent application Ser.
No. 09/942,347, entitled "Textured Contact Lens Package," filed on
Aug. 29, 2001 and U.S. patent application Ser. No. 10/183,133,
entitled "Contact Lens Packages, " filed on Jun. 26, 2002 disclose
solutions to this problem. The disclosure of these applications are
hereby incorporated by reference in their entirety. Even though
those methods address this problem, it is contemplated by the
inventors of this patent application that the additives of this
invention may be incorporated into the packaging of each of the
cited references.
[0018] In order to illustrate the invention the following examples
are included. These examples do not limit the invention. They are
meant only to suggest a method of practicing the invention. Those
knowledgeable in contact lenses as well as other specialties may
find other methods of practicing the invention. However, those
methods are deemed to be within the scope of this invention.
EXAMPLES
[0019] The following abbreviations are used below
1 Ampacet 40604 fatty acid amide ATOFINA Finacene Nucleated
polypropylene having a melt 3924CWZ flow of 55 g/10 minutes, ASTM
D1238. This material contains an antistat and a lubricant Atmer 163
fatty alkyl diethanolamine Reg. No. 107043-84-5 Dow Siloxane a
silicone dispersion MB50-321 Epolene E43-Wax, maleic anhydride
produced by Eastman Chemical Erucamide fatty acid amide Registry
No. 112-84-5 Exxon 1605 Exxon Achieve, PP1605, a metallocene
polypropylene having a melt flow of 32 g/10 minutes, ASTM D-1238
(L) Exxon 1654 Exxon Achieve, PP1654, a metallocene isotactic
polypropylene having a melt flow of 16 g/10 minutes, ASTM D-1238
(L) Fina EOD-001 Finacene, a metallocene and isotactic
polypropylene having a melt flow of 16 g/10 minutes, ASTM D1238
Flura Registry No. 7681-49-4 Kemamide fatty acid amide Licowax
fatty acid amide Mica Registry No. 12001-26-2 Nurcrel 535 & 932
ethylene-methacrylic acid co-polymer resin Registry No. 25053-53-6
Oleamide fatty acid amide Registry No. 301-02-0 polyHema poly
hydroxy ethylmethacylate having a molecular weight of greater than
1 MM Dalton mPDMS 800-1000 MW monomethacryloxypropyl terminated
polydimethylsiloxane Pluronic polyoxypropylene-polyoxyethylene
block co- polymer Registry No. 106392-12-5 PVP poly vinyl
pyrrolidinone, wherein KD# refers to different known molecular
weight distributions of poly vinyl pyrrolidinone Simma 2
3-methacryloxy-2-hydroxypropylo- xy)propylbis
(trimethylsiloxy)methylsilane Super-Floss anti slip/anti blocking
agent, Registry No. 61790-53-2 block Tetronic alkyoxylated amine
110617-70-4 Zeospheres anti- slip/anti blocking agent block Lens
Preparations Lens A Acquafilcon A lenses coated with polyhema
having a molecular weight of about 1,000,000. See U.S. Pat App. No.
09/957,299, entitled "Soft Contact Lenses," filed on Sep. 20, 2001,
Example 27. The coating method is disclosed in U.S. Pat. App. No.
09/921,192, entitled "Method for Correcting Articles by Mold
Transfer," filed on Aug. 2, 2001. Lens B Contact lenses prepared as
described in U.S. Pat. App. No. 60/318,536, entitled Biomedical
Devices Containing Internal wetting Agents," filed on September 10,
2001 and its non-provisional counterpart of the same title, filed
on September 6, 2002, containing by weight percent 30% Simma 2, 19%
mPDMS, 31% DMA, 6% PVP (MW 360,000), 0.8% EDGMA, 0.23% CGI81, 1.5%
Norbloc, 11% PVP (MW 2,500), 0.02% Blue Hema, 0-2 ac PDMS, 29%
t-amyl alcohol. Lens C Contact lenses prepared as described in U.S.
Pat. App. No. 60/318,536, entitled Biomedical Devices Containing
Internal wetting Agents," filed on September 10, 2001 and its
non-provisional counterpart of the same title, filed on September
6, 2002, containing by weight percent 28% Simma 2, 31% mPDMS, 23.5%
DMA, 7% PVP (MW 360,000), 1.5% TEDGMA, 0.98% CGI 1850, 2.0%
Norbloc, 6 HEMA, 0.02% Blue Hema.
Example 1
Preparation of Packages with Different Additives
[0020] Additives (identity and amounts listed in Table 1) were
mixed with polypropylene (listed below). The material was injection
molded to form the base portion of a contact lens package. The
configuration of the package is as illustrated in FIG. 1 of U.S.
Pat. No. 5,467,868 which is hereby incorporated by reference.
[0021] Contact lenses made from acquafilcon A coated with polyhema,
a silicone hydrogel, were added to individual polypropylene blister
packs having different additives containing 950 .mu.L of saline
solution and then the blister pack was heat sealed with an flexible
cover. Lenses were visually evaluated for adhesion to the package
after sterilization. The flexible cover sheet was removed and the
molded base is rotated or jiggled without spilling the saline
solution while a contact lens is observed to determine if it is
adhered to the inner surface of the molded base. Lenses that do not
adhere are free floating and pass the test. If the lenses adhere to
the molded base in any manner they fail the test. The addtitive,
its weight percentage, the number of lenses that stuck to the
package, and number of lenses that were free floating are displayed
in Table 1. This example illustrates that glycerol monostearate is
a superior additive.
2TABLE 1 Polypropylene Additive # tested # stuck Exxon 1605 none 12
12 Exxon 1605 calcium stearate 36 36 Exxon 1605 2% glycerol
monostearate 36 3 Exxon 1654 2% glycerol monostearate 84 2 Exxon
1654 none 12 12 Exxon Exxelor P1020 none 12 12 Fina EOD-0011 none
12 12 Fina EOD-0011 1% zinc stearate 12 12 Fina EOD-0011 3% zinc
stearate 12 12 FINA 3924CW@ antistat 36 36
Example 2
Consumer Test
[0022] Packages containing 2% weight percent GMS and Exxon 1605
were prepared using the method of Example 1. Contact lenses of
types A, B, and C were added to individual blister packages along
with 950 .mu.L of saline solution. The filed packages were heat
sealed with flexible covers and sterilized. The packaged lenses
were submitted to consumers. The consumers opened the packages and
evaluated the lenses for ease of removal of the lens from the
package using the following criteria and grading system
[0023] 1--very easy removal--Lens comes out without any
problems
[0024] 2--easy removal--a couple of attempts to remove the lenses,
but overall there were no real problems in removal
[0025] 3--moderate removal--several tries before lens comes out,
neither pleased or displeased
[0026] 4--difficult removal--many tries to remove with finger or
nail--removal is frustrating
[0027] 5--very difficult removal--many tries to remove with a
finger or nail, lens damage upon removal--very unacceptable
[0028] FIG. 1 illustrates the testing results for a comparison of
Lens A in a polypropylene package (control), Lens A in a package
containing 2.0% GMS where the package has an average surface
roughness (Ra) of about 2.0 .mu.m, and Len A in a package
containing 2.0% GMS. This figure shows that the roughened package
containing GMS has the highest consumer rating.
[0029] FIG. 2 illustrates the testing results for a comparison of
Lens B in a polypropylene package (control), Lens B in a package
containing 2.0% GMS where the package has an average surface
roughness (Ra) of about 2.0 am, and Len B in a package containing
2.0% GMS. This figure shows that the package containing 2.0%GMS has
the highest consumer rating.
[0030] FIG. 3 illustrates the testing results for a comparison of
Lens C in a polypropylene package (control), Lens C in a package
containing 2.0% GMS where the package has an average surface
roughness (Ra) of about 2.0 .mu.m, and Len C in a package
containing 2.0% GMS. This figure shows that the package containing
2.0% GMS has the highest consumer rating.
Example 3
Preparation of Packages with Different Additives
[0031] The testing methods and preparations of Example 1 were
repeated with different additives and lens types as per Table 2. If
"(UP)" appears in an entry, that bowl of the blister is shaped as
in U.S. Pat. No. D 458,023. When the term "Rough Bowl" appears, the
inside surface of the bowl is roughened to an Ra of 0.5 mm to 0.8
mm.
3TABLE 2 Base Resin Lens Type Tested Stuck Additive Exxon 1605 PP
Lens B 15 13 Calcium stearate (2%) Exxon 1605 PP Lens B 120 0 GMS
(2%) Exxon 1605 PP Lens C 30 0 GMS (2%) Exxon 1605 PP Lens B 15 12
Dow Siloxane MB50-321 (10%) Exxon 1605 PP Lens B 15 13 Dow Siloxane
MB50-321 (5%) Exxon 1605 PP Lens B 57 50 Ampacet 40604 99.5/.5
Erucamide Ampacet 40604 PP Lens B 15 15 Erucamide (5%) Exxon 1605
PP Lens B 15 15 Kemamide (Erucamide) (5%) Exxon 1605 PP Lens B 15
12 Superfloss anti-bock (2%) Exxon 1605 PP Lens B 15 15 Zeospheres
anti-block (2%) Exxon 1605 PP Lens B 15 14 Superfloss anti-bock
(2%) Oleamide (.2%) Exxon 1605 PP Lens B 14 13 Superfloss anti-bock
(.2%) Oleamide (.2%) Exxon 1605 PP Lens B 15 15 Talc (5%) Exxon
1605 PP Lens B 15 13 Calcium carbonate (5%) Exxon 1605 PP Lens B 15
14 Zinc stearate (5% hand blend) Exxon 1605 PP Lens B 15 15 Zinc
stearate (5% machine blend) Exxon 1605 PP Lens B 15 14 ATP (Vitamin
E) (5%) Exxon 1605 PP Lens B 15 13 Licowax (1%) Exxon 1605 PP Lens
B 15 14 Polyethyleneglycol monolaurate (5%) Exxon 1605 PP Lens B 15
15 Mica (5%) Exxon 1605 PP Lens B 175 8 Succinic Acid (5%) Exxon
1605 PP Lens B 15 13 Succinic Anhydride (5%) Exxon 1605 PP Lens B
118 22 Epolene E-43 (20% machine blend) Exxon 1605 PP Lens B 100 92
Epolene E-43 (20% machine blend) Exxon 1605 PP Lens B 127 52
Epolene E-43 (10% hand blend) Exxon 1605 PP Lens B 130 16 Epolene
E-43 (10% machine blend) Exxon 1605 PP Lens C 15 6 Epolene E-43
(10% machine blend) Exxon 1605 PP Lens B 30 22 Epolene E-43 (5%
machine blend) Exxon 1605 PP Lens C 15 3 Epolene E-43 (5% machine
blend) Exxon 1605 PP Lens B 15 15 Atmer 163 (1%) Exxon 1605 PP Lens
B 15 10 MC (5%) Exxon 1605 PP Lens B 30 2 Boric Acid (5% hand
blend) Exxon 1605 PP Lens B 215 3 Boric Acid (5% machine blend)
Exxon 1605 PP Lens C 15 0 Boric Acid (5% machine blend) Exxon 1605
PP Lens B 15 13 Boric Acid (3% hand blend) Exxon 1605 PP Lens B 15
15 Boric Acid (2% hand blend) Exxon 1605 PP Lens B 150 4 Epolene
E-43 (10% machine blend) Exxon 1605 PP Lens B 50 9 Epolene E-43
(10% machine blend) Exxon 1605 PP Lens B 50 15 Epolene E-43 (10%
machine blend) Exxon 1605 PP Lens B 50 35 Epolene E-43 (10% machine
blend) Exxon 1605 PP Lens B 255 6 PVP K90 (5.0%) Exxon 1605 PP Lens
B 98 31 PVP K90 (2.5%) Exxon 1605 PP Lens B 98 49 PVP K90 (1.25%)
Exxon 1605 PP Lens B 20 6 PVP K90 (1.0%) Exxon 1605 PP Lens B 20 10
PVP K90 (.75%) Exxon 1605 PP Lens B 20 17 PVP K90 (.5%) Exxon 1605
PP Lens C 248 5 PVP K90 (5.0%) Exxon 1605 PP Lens C 39 0 PVP K90
(10%) Blended down to 5% Exxon 1605 PP Lens C 135 42 PVP K90 (2.5%)
Exxon 1605 PP Lens C 135 54 PVP K90 (1.25%) Exxon 1605 PP Lens C 70
42 PVP K90 (1.0%) Exxon 1605 PP Lens C 70 50 PVP K90 (.75%) Exxon
1605 PP Lens C 70 60 PVP K90 (.5%) Exxon 1605 PP Lens B 15 14
Nucrel 535 - 10.5% acid comonomer (2%) Exxon 1605 PP Lens B 15 15
Nucrel 925 - 15% acid comonomer (3%) Exxon 1605 PP Lens C 15 14
Nucrel 535 - 10.5% acid comonomer (2%) Exxon 1605 PP Lens C 15 14
Nucrel 925 - 15% acid comonomer (3%) Exxon 1605 PP Lens B 15 15 2%
XNAP with Pluronic Exxon 1605 PP Lens C 15 14 2% XNAP with Pluronic
Exxon 1605 PP Lens B 15 15 Pluronic 1% Exxon 1605 PP Lens C 15 15
Pluronic 1% Exxon 1605 PP Lens B 15 11 1% Tetronic Exxon 1605 PP
Lens C 15 15 1% Tetronic Exxon 1605 PP Lens B 15 15 1% Flura Exxon
1605 PP Lens C 15 15 1% Flura Exxon 1605 PP Lens B 30 23 2%
Pluronic Exxon 1605 PP Lens C 30 16 2% Pluronic Exxon 1605 PP Lens
C 77 0 PVP K90 (5%) + Epolene E43 (5%) Exxon 1605 PP Lens B 50 0
PVP K90 (5%) + Epolene E43 (5%) Exxon 1605 PP Lens C 62 0 PVP K90
(5%) + Epolene E43 (1.5%) Exxon 1605 PP Lens B 50 0 PVP K90 (5%) +
Epolene E43 (1.5%) Exxon 1605 PP Lens C 65 0 PVP K90 (2.5%) +
Epolene E43 (1.25%) Exxon 1605 PP Lens B 50 0 PVP K90 (2.5%) +
Epolene E43 (1.25%) Exxon 1605 PP Lens C 115 10 PVP K90 (1%) +
Epolene E43 (1%) Exxon 1605 PP Lens B 100 11 PVP K90 (1%) + Epolene
E43 (1%) Exxon 1605 PP Lens C 30 0 PVP K29/31 (5%) Exxon 1605 PP
Lens C 30 0 PVP K60 (5%) Exxon 1605 PP Lens B 50 0 PVP K90 (1%) +
Rough Bowl (UP) Exxon 1605 PP Lens C 50 0 PVP K90 (1%) + Rough Bowl
(UP) Exxon 1605 PP Lens B 170 0 Epolene E43 (1%) + Rough Bowl Exxon
1605 PP Lens C 200 0 Epolene E43 (1%) + Rough Bowl
* * * * *